Analyst picks & changes
(CNTO)
Business: Biopharmaceuticals
Morgan Stanley analyst Eric Hecht maintained his "buy" on the Malvern, Penn., company's shares following second quarter results below the Street consensus estimate of a loss of 13 cents.
Gathering data...
(CNTO)
Business: Biopharmaceuticals
Morgan Stanley analyst Eric Hecht maintained his "buy" on the Malvern, Penn., company's shares following second quarter results below the Street consensus estimate of a loss of 13 cents.